AllianceChicago

alliancechicago.org

AllianceChicago is a leading health organization whose mission is to improve personal, community, and public health through innovative collaboration. We accomplish this through three core areas of focus: Health Care Collaboration Providing exemplary, innovative health services that unite health care providers and consumers to optimize effectiveness, efficiency, experience, and outcomes.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

MCMASTER, SARTORIUS STEDIM BIOTECH TEAM UP TO ADVANCE BIOMANUFACTURING PROCESSES WITH NEXT-GEN TECH

Sartorius Stedim Biotech S.A | August 23, 2021

news image

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has entered into a partnership with McMaster University to improve manufacturing processes of antibody and virus-based treatments for diseases such as COVID-19, cancers, and genetic disorders. Using a state-of-the-art multi-column chromatography system provided by Sartorius Stedim Biotech, the McMaster team will "perfect" a process for the purification of therapeutic viruses that...

Read More

Cell and Gene Therapy

TUMORGEN AND PHENOVISTA CAPTURE THE SEEDS THAT DRIVE CANCER METASTASIS

TumorGen Inc. and PhenoVista Biosciences LLC | September 09, 2022

news image

TumorGen Inc., and PhenoVista Biosciences LLC have successfully isolated and characterized metastatic cancer cell clusters from the blood of lung cancer patients’, validating TumorGen’s novel MCCC capture technology. This achievement is a critical milestone in developing anti-metastatic drugs, called “cluster busters,” which will target these cells and prevent cancer metastasis. “Anti-metastatic therapies that can stop tumors fro...

Read More

Industrial Impact

PARTEK AND AGILENT PARTNER TO DELIVER ALISSA CUSTOMERS END-TO-END BIOINFORMATICS WORKFLOW

Partek® Incorporated | August 20, 2021

news image

Partek® Incorporated announced today they have entered into an agreement with Agilent to integrate Partek® Flow® bioinformatics software with the Agilent Alissa Clinical Informatics Platform. This integration delivers a complete end-to-end analysis workflow that is robust, flexible, and customizable to meet Agilent customer demands. Partek has also made available the Agilent pipeline for RNA-Seq inside Partek Flow. In addition, the agreement allows Agilent to resell Partek Flow softw...

Read More

Cell and Gene Therapy, Medical

BIOCENTRIQ AND PANCELLA EXECUTE RESEARCH AGREEMENT TO STUDY STEM CELL-DERIVED NATURAL KILLER CELL EXPANSION TECHNOLOGY

PRNewswire | May 03, 2023

news image

BioCentriq, Inc. and panCELLa, a Pluristyx Company, announced that they have signed a research agreement designed to evaluate the ability of panCELLa's genetically-engineered, induced Pluripotent Stem Cell derived, feeder cells to activate and positively impact the expansion rate, total yield and potency of manufactured NK cells. BioCentriq, a contract development and manufacturing organization focused exclusively on accelerating the development and manufacturing of ce...

Read More
news image

Industrial Impact

MCMASTER, SARTORIUS STEDIM BIOTECH TEAM UP TO ADVANCE BIOMANUFACTURING PROCESSES WITH NEXT-GEN TECH

Sartorius Stedim Biotech S.A | August 23, 2021

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has entered into a partnership with McMaster University to improve manufacturing processes of antibody and virus-based treatments for diseases such as COVID-19, cancers, and genetic disorders. Using a state-of-the-art multi-column chromatography system provided by Sartorius Stedim Biotech, the McMaster team will "perfect" a process for the purification of therapeutic viruses that...

Read More
news image

Cell and Gene Therapy

TUMORGEN AND PHENOVISTA CAPTURE THE SEEDS THAT DRIVE CANCER METASTASIS

TumorGen Inc. and PhenoVista Biosciences LLC | September 09, 2022

TumorGen Inc., and PhenoVista Biosciences LLC have successfully isolated and characterized metastatic cancer cell clusters from the blood of lung cancer patients’, validating TumorGen’s novel MCCC capture technology. This achievement is a critical milestone in developing anti-metastatic drugs, called “cluster busters,” which will target these cells and prevent cancer metastasis. “Anti-metastatic therapies that can stop tumors fro...

Read More
news image

Industrial Impact

PARTEK AND AGILENT PARTNER TO DELIVER ALISSA CUSTOMERS END-TO-END BIOINFORMATICS WORKFLOW

Partek® Incorporated | August 20, 2021

Partek® Incorporated announced today they have entered into an agreement with Agilent to integrate Partek® Flow® bioinformatics software with the Agilent Alissa Clinical Informatics Platform. This integration delivers a complete end-to-end analysis workflow that is robust, flexible, and customizable to meet Agilent customer demands. Partek has also made available the Agilent pipeline for RNA-Seq inside Partek Flow. In addition, the agreement allows Agilent to resell Partek Flow softw...

Read More
news image

Cell and Gene Therapy, Medical

BIOCENTRIQ AND PANCELLA EXECUTE RESEARCH AGREEMENT TO STUDY STEM CELL-DERIVED NATURAL KILLER CELL EXPANSION TECHNOLOGY

PRNewswire | May 03, 2023

BioCentriq, Inc. and panCELLa, a Pluristyx Company, announced that they have signed a research agreement designed to evaluate the ability of panCELLa's genetically-engineered, induced Pluripotent Stem Cell derived, feeder cells to activate and positively impact the expansion rate, total yield and potency of manufactured NK cells. BioCentriq, a contract development and manufacturing organization focused exclusively on accelerating the development and manufacturing of ce...

Read More